Price to Earnings (P/E)
since 2005
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Price to Book Value (P/BV) since 2005
- Price to Sales (P/S) since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Regeneron Pharmaceuticals Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net income (loss)1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2025 | = | ÷ | = | ÷ | |||||||
| Feb 5, 2024 | = | ÷ | = | ÷ | |||||||
| Feb 6, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 8, 2021 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2020 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 8, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 9, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 12, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 21, 2012 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2007 | = | ÷ | = | ÷ | |||||||
| Feb 28, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Regeneron Pharmaceuticals Inc. Annual Report.
The price-to-earnings (P/E) ratio exhibits significant fluctuations over the observed period. Initially, the ratio is unavailable due to negative earnings per share (EPS). A notable shift occurs beginning in 2013, with the P/E ratio increasing substantially and remaining elevated for several years before declining and stabilizing.
- Early Period (2006-2012)
- From 2006 through 2012, the company reported negative EPS, resulting in a non-calculable P/E ratio. This indicates a period of unprofitability, preventing meaningful valuation based on earnings.
- Initial Increase (2013-2015)
- The P/E ratio experiences a dramatic increase from 21.42 in 2013 to 118.44 in 2015. This surge coincides with a transition to positive and increasing EPS, suggesting growing investor confidence and a willingness to pay a premium for each dollar of earnings. The ratio peaks in 2015, indicating a potentially overvalued stock or exceptionally high growth expectations.
- Subsequent Decline and Stabilization (2016-2021)
- Following the peak in 2015, the P/E ratio demonstrates a downward trend, decreasing to 15.09 by 2021. While EPS continues to rise during this period, the rate of increase appears to be factored into the stock price, leading to a more moderate valuation. The ratio fluctuates between approximately 15 and 60 during these years.
- Recent Fluctuations (2022-2026)
- The P/E ratio exhibits renewed volatility in the later years of the observation period. It declines to a low of 8.37 in 2022, potentially reflecting concerns about future earnings growth or broader market conditions. A subsequent increase to 25.99 in 2025 suggests a partial recovery in investor sentiment. The most recent value, in 2026, is 17.76, indicating a stabilization around a level similar to that observed in 2017-2019.
Overall, the P/E ratio demonstrates a clear correlation with the company’s earnings performance. The transition from negative to positive EPS is a key driver of the initial increase, while subsequent fluctuations reflect changes in growth expectations and market sentiment. The observed trends suggest a dynamic valuation influenced by both company-specific factors and broader economic conditions.
Comparison to Competitors
Regeneron Pharmaceuticals Inc., P/E, long-term trends, comparison to competitors
| Regeneron Pharmaceuticals Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | ||||||||||||
| Feb 5, 2025 | ||||||||||||
| Feb 5, 2024 | ||||||||||||
| Feb 6, 2023 | ||||||||||||
| Feb 7, 2022 | ||||||||||||
| Feb 8, 2021 | ||||||||||||
| Feb 7, 2020 | ||||||||||||
| Feb 7, 2019 | ||||||||||||
| Feb 8, 2018 | ||||||||||||
| Feb 9, 2017 | ||||||||||||
| Feb 11, 2016 | ||||||||||||
| Feb 12, 2015 | ||||||||||||
| Feb 13, 2014 | ||||||||||||
| Feb 15, 2013 | ||||||||||||
| Feb 21, 2012 | ||||||||||||
| Feb 17, 2011 | ||||||||||||
| Feb 18, 2010 | ||||||||||||
| Feb 26, 2009 | ||||||||||||
| Feb 27, 2008 | ||||||||||||
| Mar 12, 2007 | ||||||||||||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Regeneron Pharmaceuticals Inc., P/E, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Regeneron Pharmaceuticals Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Feb 4, 2026 | ||
| Feb 5, 2025 | ||
| Feb 5, 2024 | ||
| Feb 6, 2023 | ||
| Feb 7, 2022 | ||
| Feb 8, 2021 | ||
| Feb 7, 2020 | ||
| Feb 7, 2019 | ||
| Feb 8, 2018 | ||
| Feb 9, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 21, 2012 | ||
| Feb 17, 2011 | ||
| Feb 18, 2010 | ||
| Feb 26, 2009 | ||
| Feb 27, 2008 | ||
| Mar 12, 2007 | ||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Regeneron Pharmaceuticals Inc., P/E, long-term trends, comparison to industry (health care)
| Regeneron Pharmaceuticals Inc. | Health Care | |
|---|---|---|
| Feb 4, 2026 | ||
| Feb 5, 2025 | ||
| Feb 5, 2024 | ||
| Feb 6, 2023 | ||
| Feb 7, 2022 | ||
| Feb 8, 2021 | ||
| Feb 7, 2020 | ||
| Feb 7, 2019 | ||
| Feb 8, 2018 | ||
| Feb 9, 2017 | ||
| Feb 11, 2016 | ||
| Feb 12, 2015 | ||
| Feb 13, 2014 | ||
| Feb 15, 2013 | ||
| Feb 21, 2012 | ||
| Feb 17, 2011 | ||
| Feb 18, 2010 | ||
| Feb 26, 2009 | ||
| Feb 27, 2008 | ||
| Mar 12, 2007 | ||
| Feb 28, 2006 |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).